Scinai Immunotherapeutics Reports 9-Month 2025 Results
Ticker: SCNI · Form: 6-K · Filed: Dec 2, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: results, cdmo, pipeline-update
TL;DR
Scinai's 9-month 2025 results show CDMO growth & NanoAbs pipeline moving forward.
AI Summary
On December 2, 2025, Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K to report its nine-month 2025 results. The company highlighted continued growth in its Contract Development and Manufacturing Organization (CDMO) business and advancements in its NanoAbs pipeline.
Why It Matters
This filing provides investors with an update on Scinai's financial performance and strategic progress, particularly concerning its CDMO services and innovative NanoAbs technology.
Risk Assessment
Risk Level: medium — The company is in the biotechnology sector, which is inherently risky due to long development cycles and regulatory hurdles, though the report focuses on operational progress rather than clinical trial outcomes.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer and subject of the report
- BiondVax Pharmaceuticals Ltd. (company) — Former name of Scinai Immunotherapeutics Ltd.
- December 2, 2025 (date) — Date of the press release and filing
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is filed to report the nine-month 2025 results of Scinai Immunotherapeutics Ltd., as detailed in a press release issued on December 2, 2025.
What are the key business areas highlighted in the report?
The report highlights continued growth in Scinai's Contract Development and Manufacturing Organization (CDMO) business and advancements in its NanoAbs pipeline.
When did the company change its name from BiondVax Pharmaceuticals Ltd.?
The company's name change from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd. occurred on June 24, 2014.
What is the SIC code for Scinai Immunotherapeutics Ltd.?
The Standard Industrial Classification (SIC) code for Scinai Immunotherapeutics Ltd. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Where is Scinai Immunotherapeutics Ltd. headquartered?
Scinai Immunotherapeutics Ltd. is headquartered in Jerusalem, Israel, with its principal executive offices located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus.
Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2025-12-02 11:00:51
Filing Documents
- ea0268089-6k_scinai.htm (6-K) — 12KB
- ea026808901ex99-1_scinai.htm (EX-99.1) — 40KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-25-117042.txt ( ) — 65KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: December 2, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2